Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

MSD and Owkin Forge Partnership for Cutting-Edge Digital Pathology in Cancer Diagnosis

NextEdge Admin

18 Nov 2023

2 min 1 sec

Owkin announced a collaboration with MSD (Merck in the US and Canada) to develop and commercialize microsatellite instability high (MSI-H) diagnostics for four types of cancer. The partnership aims to create a pre-screening procedure for MSI-H rates in endometrial, gastric, small intestinal, and biliary cancers, utilizing Owkin’s artificial intelligence-powered MSIntuit CRC assay. This assay, already CE-marked for colorectal cancer, applies machine learning to digitized pathology slides.

While MSI is a rare occurrence in these cancers, the collaboration seeks to leverage multimodal patient data from various academic centers and hospitals. Initially focusing on the EU, the project intends to expand the application of the assay to the new cancer types. The MSI-H tumor phenotype has shown potential prognostic and therapeutic significance, especially with the growing use of immune checkpoint inhibitor therapies.

Owkin has been actively forming collaborations for spatial omics in cancer diagnostics and drug development. As the lead sponsor of the MOSAIC project, the company aims to incorporate 10X Genomics’ spatial and single-cell technologies. Meriem Sefta, Owkin’s Chief Diagnostics Officer, highlighted the strategic alliance with MSD, emphasizing their shared mission of advancing digital diagnostics to improve patient diagnosis and treatment, addressing resource pressures, and enhancing biomarker testing to align patients with optimal treatments.